Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437207 | 1.00 | HTR7 (0.43) | HTR7CA2KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL7564361 | 0.87 | DRD4 (0.47) | CA2KCNJ5KCNJ3ALDH1A1KDM4E | |
| SCHEMBL1817280 | 0.84 | CA2 (0.43) | CA2KCNJ5KCNJ3ALDH1A1KDM4E | |
| SCHEMBL30918574 | 0.84 | CA2 (0.43) | CA2KCNJ5KCNJ3ALDH1A1KDM4E | |
| SCHEMBL9981632 | 0.84 | CA2 (0.43) | CA2KCNJ5KCNJ3ALDH1A1KDM4E | |
| SCHEMBL1817279 | 0.84 | CA2 (0.43) | CA2KCNJ5KCNJ3ALDH1A1KDM4E | |
| SCHEMBL1854159 | 0.84 | DRD4 (0.48) | CA2KCNJ5KCNJ3ALDH1A1KDM4E | |
| SCHEMBL20356443 | 0.82 | KCNJ5 (0.43) | CA2KCNJ5KCNJ3ALDH1A1KDM4E | |
| SCHEMBL20356662 | 0.82 | KCNJ5 (0.43) | CA2KCNJ5KCNJ3ALDH1A1KDM4E | |
| SCHEMBL20356767 | 0.82 | KCNJ5 (0.43) | CA2KCNJ5KCNJ3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1181017-B1 | METALLOPROTEASE INHIBITORS | PFIZER LTD (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-6511993-B1 | Substituted alpha-aminosulphonyl-acetohydroxamic acids which are inhibitors of zinc-dependent metalloprotease enzymes | PFIZER INC. | 2003-01-28 | — | — | US | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | HTR7 3967/4885CA2 3285/4885KCNJ5 4847/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | HTR7 3967/4885CA2 3285/4885KCNJ5 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.